Fig. 2: UBE2T is upregulated in the enriched CSC population and contributes to poor patient survival. | Cell Death & Disease

Fig. 2: UBE2T is upregulated in the enriched CSC population and contributes to poor patient survival.

From: The interplay of UBE2T and Mule in regulating Wnt/β-catenin activation to promote hepatocellular carcinoma progression

Fig. 2

a UBE2T expression was significantly upregulated in CSC-enriched EpCAM+ populations in the GSE5975 dataset (**p < 0.01, t test). b In the analysis of dataset GSE25097, we found upregulation of UBE2T mRNA in a cohort of 243 paired HCC and nontumor samples (***p < 0.001, t test). In addition, UBE2T was upregulated in cirrhotic samples compared with healthy donor samples (*p < 0.05, t test). c In the analysis of the Cancer Genome Atlas (TCGA), the overall and disease-free survival rates of HCC patients with high UBE2T overexpression were significantly lower than those of patients with low UBE2T expression (p = 0.0016 and p = 0.0013, respectively; log-rank test). d qPCR analysis showed that 55% of HCC patient specimens (45 out of 82 cases) showed an eightfold increase in UBE2T mRNA expression compared to that in adjacent nontumor liver tissues. e A representative photo (case #12457) showing the boundary between the nontumor (NT) and tumor (T) regions (M indicates the margin, scale bar: 200 µm). f UBE2T protein overexpression was found in 87.5% (7/8) of HCC specimens (n = 8). Immunoblots are representative of two individual experiments.

Back to article page